1. Home
  2. NVEC vs DMAC Comparison

NVEC vs DMAC Comparison

Compare NVEC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NVE Corporation

NVEC

NVE Corporation

HOLD

Current Price

$78.27

Market Cap

335.8M

Sector

Technology

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.61

Market Cap

352.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVEC
DMAC
Founded
1989
2000
Country
United States
United States
Employees
N/A
35
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.8M
352.4M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
NVEC
DMAC
Price
$78.27
$6.61
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
34.4K
214.6K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
5.22%
N/A
EPS Growth
N/A
N/A
EPS
2.12
N/A
Revenue
$25,874,694.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$36.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$55.48
$3.34
52 Week High
$82.30
$10.42

Technical Indicators

Market Signals
Indicator
NVEC
DMAC
Relative Strength Index (RSI) 75.68 44.64
Support Level $64.17 $6.56
Resistance Level $82.09 $7.36
Average True Range (ATR) 2.13 0.48
MACD 1.11 0.04
Stochastic Oscillator 99.90 50.00

Price Performance

Historical Comparison
NVEC
DMAC

About NVEC NVE Corporation

NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: